

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Type or print name of person signing certification

Signature

Date

**PATENT APPLICATION  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant: Dale L. Ludwig

Group Art Unit: 1643

Serial No.: 10/555407

Examiner:  
BLANCHARD, DAVID J

Application Date: 03 May 2004

Confirmation No.: 7544

US Nat'l Entry

Date (if applicable): 08 Jun 2007

For: FULLY HUMAN ANTIBODIES DIRECTED AGAINST THE  
HUMAN INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR

Docket No.: X18524

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the restriction requirement dated April 28, 2009, for the above-identified patent application, entry of the following election and remark is respectfully requested.

Any fees associated with this amendment may be charged to Eli Lilly Deposit Account No. 05-0840.

This paper is filed in response to the restriction requirement for which a response is due May 28, 2009. Claims 1-56 are pending in the present application and are subject to the following restriction under 35 U.S.C. 121 and 372.

The restriction requirement set for the by the Examiner is as follows:

Group I, claims 1-18 and 23-33, drawn to an isolated human antibody or fragment thereof that binds IGF-IR and pharmaceutical compositions comprising such.

Group II, claims 19-22, drawn to nucleic acid, vectors and host cells encoding human antibody or fragment thereof that binds IGF-IR.

Group III, claims 34 and 36-40, drawn to a method of treating acromegaly comprising administering a human antibody or fragment thereof that binds IGF-IR.

Group IV, claims 34 and 36-40, drawn to a method of treating retinal neovascularization comprising administering a human antibody or fragment thereof that binds IGF-IR.

Group V, claims 34 and 36-40, drawn to a method of treating psoriasis comprising administering a human antibody or fragment thereof that binds IGF-IR.

Group VI, claims 34, 37 and 41-56, drawn to a method of reducing tumor growth comprising administering a human antibody or fragment thereof that binds IGF-IR.

**Election**

Applicants herein elects Group I, claims 1-18 and 23-33 without traverse. The Examiner has also required a restriction between the product and process claims. As such, Applicant reserves the right for to rejoin the withdrawn process claims in accordance to MPEP § 821.04 if the product claims are found allowable.